14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
MRNA vs TECH: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Bio-Techne Corp. (TECH) captures the overall head-to-head institutional edge over Moderna, Inc. (MRNA) on higher Unified Composite conviction (55.4/100 HOLD vs. 40.3/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while MRNA wins 4–2 across the 6-pillar growth and valuation breakdown. MRNA trades at $195.00 (23.0x Forward P/E, -80.8% operating margin) versus TECH at $72.67 (42.8x Forward P/E, 21.7% operating margin).
Growth vs. Quality Trade-Off: TECH earns the overall head-to-head edge with a stronger Unified Composite Score (55.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.33β · 2% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile TECH is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs TECH. Trailing 12-month operating profitability (MRNA -80.8% vs TECH 21.7%) and valuation multiples (MRNA 23.0x vs TECH 42.8x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $11.4B market capitalization and 21.7% operating margin.
OpEx & R&D Reinvestment44.5% of Rev ($547M)
90D Engineering Disclosures0 Published
Investor FAQ MRNA vs TECH Key Questions & Quantitative Answers
As of Nov 20, 2026, Bio-Techne Corp. (TECH) captures the overall head-to-head institutional edge over Moderna, Inc. (MRNA) on higher Unified Composite conviction (55.4/100 HOLD vs. 40.3/100 SELL) after splitting the core matrix 6–4 (led by Profitability & Quality, Balance Sheet & Cash Flow), while MRNA wins 4–2 across the 6-pillar growth and valuation breakdown. MRNA trades at $195.00 (23.0x Forward P/E, -80.8% operating margin) versus TECH at $72.67 (42.8x Forward P/E, 21.7% operating margin). Growth vs. Quality Trade-Off: TECH earns the overall head-to-head edge with a stronger Unified Composite Score (55.4/100 HOLD vs. MRNA 40.3/100 SELL) and 0.33β · 2% Vol risk profile, whereas MRNA leads top-line expansion (+29.2% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: MRNA trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 41.5); meanwhile TECH is in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
MRNA leads the Growth & Scale pillar: MRNA posts +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin), compared with TECH at +4.6% YoY revenue growth and -25.0% YoY earnings growth on $1.23B TTM revenue (66.2% gross margin, 21.7% operating margin). On trailing 12-month operating scale, MRNA generates $2.52B in USD-normalized revenue versus $1.23B for TECH. In operating R&D and SG&A reinvestment, MRNA deploys 38.8% of Rev ($980M) (0 90-day corporate R&D disclosures) versus 44.5% of Rev ($547M) (0 disclosures) for TECH.
MRNA screens cheaper on headline valuation multiples. MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin), whereas TECH trades at 42.8x Forward P/E, 66.7x Trailing P/E, 2.17x PEG, and 9.3x EV/Revenue (26.5% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MRNA (-34.5% ROE) versus TECH (8.3% ROE) capital efficiency.
In options market volatility and institutional positioning, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk). By comparison, TECH carries 40.9% implied volatility (6th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.33β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.